Product Banner

Molecular Diagnostic Market and Testing - Overview

Molecular Diagnostic Market and Testing - Overview
$2,495.00
$2,495.00
  • Jan 02, 2014
  • 122 pages
  • Insight Pharma Reports
Abstract
Molecular Diagnostics: An Insight to Rising Markets and Trends in Cancer and Prenatal Technologies covers market research, relevant disease background, and a number of rising technologies available to physicians and clinicians in the cancer and prenatal space. This report focuses on market background of the areas that are covered, including lung, breast, thyroid and blood cancers (specifically leukemia and lymphoma), as well as pre-conception genetic information and prenatal diagnostics.


Included in this Report:

Cancer diagnostics companies interviewed include: GeneCentric, Veracyte, Adaptive Biotechnologies
Genetic and prenatal diagnostics research companies including GenePeeks and Verinata Health
Comprehensive coverage of survey results (n=123) from the various companies and researchers working in molecular diagnostics.
A company directory which was created for this report. This includes several seasoned and emerging companies, their areas of focus, and the status of their technologies.
Table of Contents
Executive Summary

PART I: Introduction and Market Background

CHAPTER 1: The Focus of This Report

CHAPTER 2: Market Trends and Adaptability

Lung cancer diagnostics market growth
Breast cancer diagnostics market growth
Thyroid cancer diagnostics market growth
Blood cancer diagnostics market growth
Prenatal diagnostics market growth
PART II: Cancer Diagnostics

CHAPTER 3: Lung Cancer

Types of lung cancer
Risk factors
Incidence
Symptoms and early detection
Targeted therapies
CHAPTER 4: Breast Cancer

Types of breast cancer
Risk factors
Incidence
Symptoms and early detection
Treatments for breast cancer
CHAPTER 5: GeneCentric

Company background
Lung Subtype Platform (LSP)
Hypoxia Signature Platform
GeneCentric outlook
Interview with Myla Lai-Goldman
Company background
Platforms
Future outlook
CHAPTER 6: Thyroid Cancer

Types
Risk
Symptoms and early detection
Therapeutic options
CHAPTER 7: Veracyte

Company background
Afirma Thyroid FNA Analysis
Validation
Competitive advantage
Future growth plans
Interview with Bonnie Anderson
Company background
Afirma Thyroid FNA Analysis
Competitive advantage
Challenges encountered
Future improvements
CHAPTER 8: Blood-Based Cancers

Leukemia
Types
Risk factors, symptoms and early detection
Therapeutic options
Lymphoma
Types
Classic Hodgkin disease
Nodular lymphocyte predominant Hodgkin disease
Non-Hodgkin lymphoma
Risk factors
Symptoms and therapeutic options
CHAPTER 9: Adaptive Biotechnologies Corporation

Company background
ClonoSEQ
Validation
Areas of improvement
Competitive advantage
Future endeavors
Interview with Chad Robins
Company background
ClonoSEQ
Areas of improvement
Challenges encountered
Competitive advantage
Future endeavors
PART III: Genetic Information and Prenatal Diagnostics

CHAPTER 10: Genetic Information and Prenatal Testing

Genetic information
Prenatal testing
Sequence-based cell-free DNA testing
Fetal cell isolation
CHAPTER 11: GenePeeks

Company background
Patented technology
How does the process work?
Validation
Accuracy and sensitivity
Areas of improvement
Competitive advantage
Future applications
Interview with Anne Morriss
Company background
Patented technology
Competitive advantage
Areas of improvement and future outlook
CHAPTER 12: Verinata Health

Company background
The verifi® prenatal test
Clinical validation and reimbursement
Customer feedback
CHAPTER 13: Testing Specifications

PART IV: Survey Demographics

CHAPTER 14: Survey Results

Survey demographics
Areas of study
Rising technologies
Challenges encountered
PART V: Company Directory
List of Figures
Figure 2.1: Growth in molecular diagnostics
Figure 2.2: Growth in lung cancer diagnostics
Figure 2.3: Growth in breast cancer diagnostics
Figure 2.4: Growth in thyroid cancer diagnostics
Figure 2.5: Growth in blood cancer diagnostics
Figure 2.6: Growth in prenatal diagnostics
Figure 3.1: Lung cancer deaths in men and women in the US
Figure 4.1: Breast cancer deaths in women in the US
Figure 14.1: Number of researchers working in molecular diagnostics
Figure 14.2: Survey demographics
Figure 14.3: Areas of study
Figure 14.4: Specific area of diagnostics
Figure 14.5: Technology status
Figure 14.6: Type of technologies in development
Figure 14.7: Technology basis
Figure 14.8: Targets of interest
Figure 14.9: Challenges encountered
Figure 15.1: Rank of Clients Purchasing Technologies from Selected Vendors
List of Tables
Table 3.1: Targets and their clinical status
Table 4.1: Targeted therapies for breast cancer
Table 5.1: Lung Subtype Platform and Hypoxia Signature Platform
Table 6.1: Thyroid cancer stages
Table 7.1: Afirma Thyroid FNA Analysis Platform
Table 8.1: Classic Hodgkin disease types and characteristics
Table 8.2: B-cell and T-cell non-Hodgkin lymphomas
Table 9.1: clonoSEQ platform specifications
Table 11.1: Virtual Genome Platform
Table 12.1: verifi® prenatal test performance for aneuploidies
Table 12.2: verifi® prenatal test performance for sex chromosomes
Table 12.3: verifi® prenatal test
Companies Covered